Skip to main content
Top
Published in: Lasers in Medical Science 1/2022

01-02-2022 | Original Article

Photobiomodulation-blue and red LED: protection or cellular toxicity? In vitro study with human fibroblasts

Authors: Fabiana dos Santos Ferreira, Francine Carla Cadoná, Alessandra Rafaeli Aurélio, Thaís Nogueira de Oliveira Martins, Hedioneia Maria Foletto Pivetta

Published in: Lasers in Medical Science | Issue 1/2022

Login to get access

Abstract

Photobiomodulation is widely used in clinical practice, and there is increasing interest in using this tool to treat numerous dysfunctions in living organisms. Therefore, this study aimed to verify the action of blue and red light-emitting diode light in cells. Human fibroblast cell line (HFF-1) were irradiated by blue (470 nm) or red (658 nm) light at doses of 4 and 18 J/cm2, respectively. Laboratory analyses were carried out to check for viability, proliferation, cell death, and the formation of reactive oxygen and nitric oxide species. The blue light demonstrated cell protection potential by reducing free radical formation and protecting the cell membrane by decreasing double-stranded DNA strands. On the other hand, the red light showed less potential for cell protection due to the risk of associating more significant nitric oxide formation with increased reactive oxygen species formation, in addition to having a greater amount of extracellular DNA. Cell damage prevention is a potential beneficial effect of blue light at 18 J/cm2. Despite the consolidated effects of red light in treating wounds, there was a potential toxic effect of this wavelength in the doses studied. Given the above, new studies relating these parameters with pathological cells or aggressors that simulate damage may offer results that can better support clinical practice.
Literature
1.
go back to reference Robijns J, Censabella S, Claes S, Pannekoeke L, Bussé L, Colson D, Kaminski I, Bulens P, Maes A, Noé L, Brosens M, Timmermans A, Lambrichts I, Somers V, Mebis J (2018) Prevention of acute radiodermatitis by photobiomodulation: a randomized, placebo-controlled trial in breast cancer patients (TRANSDERMIS trial). Lasers Surg Med 50:763–771. https://doi.org/10.1002/lsm.22804CrossRef Robijns J, Censabella S, Claes S, Pannekoeke L, Bussé L, Colson D, Kaminski I, Bulens P, Maes A, Noé L, Brosens M, Timmermans A, Lambrichts I, Somers V, Mebis J (2018) Prevention of acute radiodermatitis by photobiomodulation: a randomized, placebo-controlled trial in breast cancer patients (TRANSDERMIS trial). Lasers Surg Med 50:763–771. https://​doi.​org/​10.​1002/​lsm.​22804CrossRef
11.
go back to reference Keemss K, Pfaff SC, Born M, Liebmann J, Merk HF, von Felbert V (2016) Prospective, randomized study on the efficacy and safety of local UV-free blue light treatment of eczema [published correction appears in Dermatology.;232(4):522]. Dermatology. 232(4):496–502. https://doi.org/10.1159/000448000CrossRefPubMed Keemss K, Pfaff SC, Born M, Liebmann J, Merk HF, von Felbert V (2016) Prospective, randomized study on the efficacy and safety of local UV-free blue light treatment of eczema [published correction appears in Dermatology.;232(4):522]. Dermatology. 232(4):496–502. https://​doi.​org/​10.​1159/​000448000CrossRefPubMed
23.
go back to reference Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43(2):109–142PubMed Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43(2):109–142PubMed
Metadata
Title
Photobiomodulation-blue and red LED: protection or cellular toxicity? In vitro study with human fibroblasts
Authors
Fabiana dos Santos Ferreira
Francine Carla Cadoná
Alessandra Rafaeli Aurélio
Thaís Nogueira de Oliveira Martins
Hedioneia Maria Foletto Pivetta
Publication date
01-02-2022
Publisher
Springer London
Published in
Lasers in Medical Science / Issue 1/2022
Print ISSN: 0268-8921
Electronic ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-021-03290-5

Other articles of this Issue 1/2022

Lasers in Medical Science 1/2022 Go to the issue